NCT04619433

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.

Detailed description

The study is being conducted to evaluate the efficacy and safety of Camrelizumab in combination with Famitinib plus chemotherapy in subjects with NSCLC.

Conditions

• Non-squamous Non-small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab;Pemetrexed and Carboplatin; Famitinib;	Part 1: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
DRUG	Camrelizumab;Pemetrexed and Carboplatin;Placebo	Part 2: Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo

Timeline

• Start date: 2021-02-01
• Primary completion: 2025-08-16
• Completion: 2025-08-16
• First posted: 2020-11-06
• Last updated: 2025-09-23

Locations

7 sites across 1 country: China